Form 8-K - Current report:
SEC Accession No. 0001213900-22-025731
Filing Date
2022-05-12
Accepted
2022-05-12 08:30:59
Documents
15
Period of Report
2022-05-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea159780-8k_abvcbio.htm   iXBRL 8-K 27896
2 FORM OF SECURITIES PURCHASE AGREEMENT, BETWEEN THE COMPANY AND THE PURCHASERS ea159780ex1-1_abvcbio.htm EX-1.1 199250
3 FORM OF WARRANT ea159780ex4-1_abvcbio.htm EX-4.1 91249
4 PRESS RELEASE DATED MAY 12, 2022 ea159780ex99-2_abvcbio.htm EX-99.2 10166
  Complete submission text file 0001213900-22-025731.txt   579844

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE abvc-20220511.xsd EX-101.SCH 3057
6 XBRL LABEL FILE abvc-20220511_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE abvc-20220511_pre.xml EX-101.PRE 22611
9 EXTRACTED XBRL INSTANCE DOCUMENT ea159780-8k_abvcbio_htm.xml XML 3496
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 22915837
SIC: 2834 Pharmaceutical Preparations